<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112589</url>
  </required_header>
  <id_info>
    <org_study_id>FLAG-QUIDA</org_study_id>
    <nct_id>NCT04112589</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment</brief_title>
  <official_title>A Multicenter, Prospective, Non-randomized, Phase I-II Trial to Assess the Efficacy and Safety of the Combination of Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syntax for Science, S.L</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, non-randomized, Phase I-II trial to assess the efficacy&#xD;
      and safety of the combination of oral quizartinib and FLAG-IDA chemotherapy schedule&#xD;
      (FLAG-QUIDA regimen) in first relapsed/refractory AML (acute myeloid leukemia) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients of approximately 20 sites (in Spain and Portugal) will receive FLAG-QUIDA regimen&#xD;
      followed by transplantation, when possible, with up to 3 optional consolidation cycles. All&#xD;
      patients in CR/CRi (complete remission / complete remission with incomplete hematologic&#xD;
      recovery) will receive a maintenance schedule.&#xD;
&#xD;
      A Phase I (dose escalation) will be performed at 40 mg x 14 days of quizartinib in the first&#xD;
      3 patients, and if no dose-limiting toxicity (DLT) is observed, the next cohort of patients&#xD;
      will receive 60 mg x 14 days. There is also the possibility of de-escalation cohorts at 60 mg&#xD;
      x 7 days and at 40 mg x 7 days. Patients participating in the Phase I will receive the&#xD;
      allocated dose level, and therefore, they must not receive strong CYP3A4 inhibitors&#xD;
      concomitantly with quizartinib The Phase II will include 68 patients treated at the RP2D&#xD;
      (recommended phase 2 dose). A 1-year maintenance schedule starting at 30 mg will be increased&#xD;
      to 60 mg/day if appropriate.&#xD;
&#xD;
      Patients will be followed up for a minimum period of 1 year since the first visit of the last&#xD;
      patient included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study consists of a dose escalation-dose finding part (phase I) and a phase II part.&#xD;
Subjects will have an induction of 1 cycle, by an alloSCT (allogeneic hematopoietic stem cell transplantation) in CR/CRi, when possible, with up to 3 optional HiDAC (high dose Cytarabine ) consolidation cycles. All patients in CR/CRi will receive a maintenance schedule (12 months, 12 cycles).&#xD;
The phase I portion will progress from starting level dose 1 (40mg 14 days) to level dose 2 (60 mg 14 days). De-escalation to level dose -1 (60mg 7 days) or level dose -2 (40mg 7 days) may be necessary to be explored.&#xD;
Once the RP2D is established, the phase II will start.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RP2D finding</measure>
    <time_frame>1 cycle (4 weeks)</time_frame>
    <description>Maximum Tolerated dose of the combination of quizartinib a FLAG-IDA regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate CR/CRi</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the rate of CR/CRi after one cycle of FLAG-QUIDA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>time from the first documentation of remission to the documentation of disease recurrence or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>Number of days from randomization until death from any cause</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Level dose 1 - 40mg, 14 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive an induction cycle (40mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level dose 2 - 60mg, 14 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive an induction cycle (60mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level dose -1 - 60mg 7days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive an induction cycle (60mg Quizartinib for 7 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level dose -2 - 40mg 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive an induction cycle (40mg Quizartinib for 7days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quizartinib</intervention_name>
    <description>Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.</description>
    <arm_group_label>Level dose -1 - 60mg 7days</arm_group_label>
    <arm_group_label>Level dose -2 - 40mg 7 days</arm_group_label>
    <arm_group_label>Level dose 1 - 40mg, 14 days</arm_group_label>
    <arm_group_label>Level dose 2 - 60mg, 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2 intravenous days 1 to 4 of the cycle</description>
    <arm_group_label>Level dose -1 - 60mg 7days</arm_group_label>
    <arm_group_label>Level dose -2 - 40mg 7 days</arm_group_label>
    <arm_group_label>Level dose 1 - 40mg, 14 days</arm_group_label>
    <arm_group_label>Level dose 2 - 60mg, 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle</description>
    <arm_group_label>Level dose -1 - 60mg 7days</arm_group_label>
    <arm_group_label>Level dose -2 - 40mg 7 days</arm_group_label>
    <arm_group_label>Level dose 1 - 40mg, 14 days</arm_group_label>
    <arm_group_label>Level dose 2 - 60mg, 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>10 mg/ 2 intravenous days 1 to 3 of the cycle</description>
    <arm_group_label>Level dose -1 - 60mg 7days</arm_group_label>
    <arm_group_label>Level dose -2 - 40mg 7 days</arm_group_label>
    <arm_group_label>Level dose 1 - 40mg, 14 days</arm_group_label>
    <arm_group_label>Level dose 2 - 60mg, 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glycosylated G-CSF</intervention_name>
    <description>daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle</description>
    <arm_group_label>Level dose -1 - 60mg 7days</arm_group_label>
    <arm_group_label>Level dose -2 - 40mg 7 days</arm_group_label>
    <arm_group_label>Level dose 1 - 40mg, 14 days</arm_group_label>
    <arm_group_label>Level dose 2 - 60mg, 14 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent in accordance with national, local, and institutional&#xD;
             guidelines. The patient must provide informed consent prior to the first screening&#xD;
             procedure. Informed consent form must be signed by the patient and the Investigator.&#xD;
&#xD;
          2. Patients aged ≥ 18 years old and ≤70 years old at the time of screening.&#xD;
&#xD;
          3. First R/R AML defined as:&#xD;
&#xD;
               -  First relapse after frontline intensive chemotherapy (with or without prior&#xD;
                  alloSCT), irrespectively of the duration of the first CR. Patients previously&#xD;
                  treated with a FLT3 inhibitor different from quizartinib, can be included.&#xD;
&#xD;
               -  First refractory disease (defined as patients not achieving at least a PR after&#xD;
                  first induction cycle and/or not achieving CR/CRi after first 2 cycles). Patients&#xD;
                  previously treated with a FLT3 inhibitor different from quizartinib, can be&#xD;
                  included.&#xD;
&#xD;
          4. Non-APL AML.&#xD;
&#xD;
          5. Considered for intensive approach as per Investigator judgment.&#xD;
&#xD;
          6. ECOG 0-2.&#xD;
&#xD;
          7. No contraindications for quizartinib.&#xD;
&#xD;
          8. No contraindications for intensive chemotherapy.&#xD;
&#xD;
          9. No severe organ function abnormalities.&#xD;
&#xD;
         10. No active relevant GVHD.&#xD;
&#xD;
         11. For the Phase II, FLT3-ITD patients will represent 50% of the study cohort (FLT3-TKD&#xD;
             are not excluded but included in the FLT3-ITD-WT group).&#xD;
&#xD;
         12. Female patients of child-bearing potential must have a negative serum pregnancy test&#xD;
             at screening and agree to use reliable methods of contraception upon enrollment,&#xD;
             during the treatment period and for 6 months following the last dose of&#xD;
             investigational drug or cytarabine, whichever is later.&#xD;
&#xD;
         13. Male patients must use a reliable method of contraception (if sexually active with a&#xD;
             female of child-bearing potential) upon enrollment, during the treatment period, and&#xD;
             for 6 months following the last dose of investigational drug or cytarabine, whichever&#xD;
             is later.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with genetic diagnosis of acute promyelocytic leukemia.&#xD;
&#xD;
          2. Blastic phase of bcr/abl chronic myeloid leukemia.&#xD;
&#xD;
          3. Patients with other neoplastic disease, for whom the Investigator has clinical&#xD;
             suspicion of active disease at the time of enrollment. Note: Patients with adequately&#xD;
             treated early stage squamous cell carcinoma of the skin, basal cell carcinoma of the&#xD;
             skin, or cervical intraepithelial neoplasia are eligible for this study. Hormonal or&#xD;
             adjuvant therapies will be allowed for breast cancer or prostate cancer if they are on&#xD;
             a stable dose for at least 2 weeks prior to first dose.&#xD;
&#xD;
          4. Presence of any severe psychiatric disease or physical condition/comorbidity that,&#xD;
             according to the physician´s criteria, contraindicates the inclusion of the patient in&#xD;
             the clinical trial&#xD;
&#xD;
          5. Serum creatinine ≥ 250 μmol/l (≥ 2.5 mg/dL) (unless it is attributable to AML&#xD;
             activity).&#xD;
&#xD;
          6. Bilirubin, alkaline phosphatase, or SGOT &gt;3 times the upper normal limit (unless it is&#xD;
             attributable to AML activity).&#xD;
&#xD;
          7. Uncontrolled or significant cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  Symptomatic bradycardia of less than 50 beats per minute, unless the subject has&#xD;
                  a pacemaker.&#xD;
&#xD;
               -  QTcF &gt;450 ms at screening. Note: QTcF will be derived from the mean of triplicate&#xD;
                  readings.&#xD;
&#xD;
               -  Diagnosis of or suspicion of long QT syndrome (including family history of long&#xD;
                  QT syndrome)&#xD;
&#xD;
               -  History of clinically relevant ventricular arrhythmias (e.g., ventricular&#xD;
                  tachycardia, ventricular fibrillation, or Torsade de Pointes).&#xD;
&#xD;
               -  History of second- (Mobitz II) or third-degree heart block (subjects with&#xD;
                  pacemakers are eligible if they have no history of fainting or clinically&#xD;
                  relevant arrhythmias while using the pacemaker).&#xD;
&#xD;
               -  History of uncontrolled angina pectoris or myocardial infarction within 6months&#xD;
                  prior to Screening.&#xD;
&#xD;
               -  History of New York Heart Association Class 3 or 4 heart failure.&#xD;
&#xD;
               -  Complete left bundle branch block.&#xD;
&#xD;
               -  Right bundle branch and left anterior hemiblock (bifascicular block)&#xD;
&#xD;
               -  Infarction (MI) within 3 months.&#xD;
&#xD;
               -  Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥ 110 mmHg&#xD;
&#xD;
               -  A previously known left ventricle ejection fraction &lt;45%&#xD;
&#xD;
          8. Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics,&#xD;
             antivirals, or antifungals within one week prior to first dose; however, prophylactic&#xD;
             use of these agents is acceptable even if parenteral.&#xD;
&#xD;
          9. Active hepatitis B or hepatitis C infection.&#xD;
&#xD;
         10. Previously known and documented human immunodeficiency virus (HIV) infection (HIV&#xD;
             testing is not required as part of this study).&#xD;
&#xD;
         11. Active acute or chronic GVHD requiring prednisone &gt;10 mg or equivalent corticosteroid&#xD;
             daily&#xD;
&#xD;
         12. Any patients with known significant impairment in gastrointestinal function or&#xD;
             gastrointestinal disease that may significantly alter the absorption of quizartinib&#xD;
&#xD;
         13. History of hypersensitivity to any excipients in the quizartinib tablets.&#xD;
&#xD;
         14. Females who are pregnant or breastfeeding.&#xD;
&#xD;
         15. Isolated extramedullary R/R AML.&#xD;
&#xD;
         16. Only applicable to patients screened after the first cohort of 34 patients of the&#xD;
             Phase II has been achieved (e.g., FLT3-ITD negative): patients must have a&#xD;
             confirmation of FLT3-ITD status at relapse, and this must correspond to the&#xD;
             non-achieved cohort (e.g. FLT3-ITD positive).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pau Montesinos, MD</last_name>
    <role>Study Director</role>
    <affiliation>Trial Coordinator, Institution Contact</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pau Montesinos, MD</last_name>
    <phone>+34 961245876</phone>
    <email>montesinos_pau@gva.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitário de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia do Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Gil Cortés</last_name>
    </contact>
    <investigator>
      <last_name>Cristina Gil Cortés</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català D'Oncologia-Hospital Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Vives</last_name>
    </contact>
    <investigator>
      <last_name>Susana Vives</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català D'Oncologia-Hospital Duran I Reynals</name>
      <address>
        <city>Bellvitge</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Arnan</last_name>
    </contact>
    <investigator>
      <last_name>Montserrat Arnan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta Del Mar</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Marchante</last_name>
    </contact>
    <investigator>
      <last_name>Inmaculada Marchante</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña</name>
      <address>
        <city>Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Noriega Concepción</last_name>
    </contact>
    <investigator>
      <last_name>Victor Noriega Concepción</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Miguel Bergua</last_name>
    </contact>
    <investigator>
      <last_name>Juan Miguel Bergua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefina Serrano López</last_name>
    </contact>
    <investigator>
      <last_name>Josefina Serrano López</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Girona - Hospital Josep Trueta</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosa Coll</last_name>
    </contact>
    <investigator>
      <last_name>Rosa Coll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Jerez de La Frontera</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eusebio Martín</last_name>
    </contact>
    <investigator>
      <last_name>Eusebio Martín</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Gran Canaria Dr. Negrin</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Rodríguez Medina</last_name>
    </contact>
    <investigator>
      <last_name>Carlos Rodríguez Medina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Insular-Materno Infantil</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Torres</last_name>
    </contact>
    <investigator>
      <last_name>Laura Torres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Herrera Puente</last_name>
    </contact>
    <investigator>
      <last_name>Pilar Herrera Puent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquín Martínez López</last_name>
    </contact>
    <investigator>
      <last_name>Joaquín Martínez López</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de La Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Fernández</last_name>
    </contact>
    <investigator>
      <last_name>Alfonso Fernández</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Bernal del Castillo</last_name>
    </contact>
    <investigator>
      <last_name>Teresa Bernal del Castillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Novo</last_name>
    </contact>
    <investigator>
      <last_name>Andrés Novo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Alfonso Piérola</last_name>
    </contact>
    <investigator>
      <last_name>Ana Alfonso Piérola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Rodríguez Arbolí</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo Rodríguez Arbolí</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Joan Xxiii de Tarragona</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Cervera</last_name>
    </contact>
    <investigator>
      <last_name>Marta Cervera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebeca Rodriguez Veiga</last_name>
    </contact>
    <investigator>
      <last_name>Rebeca Rodriguez Veiga Veiga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010 Jan 21;115(3):453-74. doi: 10.1182/blood-2009-07-235358. Epub 2009 Oct 30. Review.</citation>
    <PMID>19880497</PMID>
  </reference>
  <reference>
    <citation>Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood. 2013 Feb 14;121(7):1077-82. doi: 10.1182/blood-2012-08-234492. Epub 2012 Dec 14. Review.</citation>
    <PMID>23243288</PMID>
  </reference>
  <reference>
    <citation>Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000 Mar;14(3):476-9. Review.</citation>
    <PMID>10720145</PMID>
  </reference>
  <reference>
    <citation>Yavuz S, Paydas S, Disel U, Sahin B. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Am J Ther. 2006 Sep-Oct;13(5):389-93.</citation>
    <PMID>16988532</PMID>
  </reference>
  <reference>
    <citation>Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol. 2003 Apr;82(4):231-5. Epub 2003 Mar 15.</citation>
    <PMID>12707726</PMID>
  </reference>
  <reference>
    <citation>de la Rubia J, Regadera A, Martín G, Cervera J, Sanz G, Martínez J, Jarque I, García I, Andreu R, Moscardó F, Jiménez C, Mollá S, Benlloch L, Sanz M. FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leuk Res. 2002 Aug;26(8):725-30.</citation>
    <PMID>12191567</PMID>
  </reference>
  <reference>
    <citation>Kim H, Park JH, Lee JH, Lee JH, Joo YD, Lee WS, Bae SH, Mo Ryoo H, Lee KH; Cooperative Study Group A for Hematology. Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study. Am J Hematol. 2009 Mar;84(3):161-6. doi: 10.1002/ajh.21351.</citation>
    <PMID>19195034</PMID>
  </reference>
  <reference>
    <citation>Bergua JM, Montesinos P, Martinez-Cuadrón D, Fernández-Abellán P, Serrano J, Sayas MJ, Prieto-Fernandez J, García R, García-Huerta AJ, Barrios M, Benavente C, Pérez-Encinas M, Simiele A, Rodríguez-Macias G, Herrera-Puente P, Rodríguez-Veiga R, Martínez-Sánchez MP, Amador-Barciela ML, Riaza-Grau R, Sanz MA; PETHEMA group. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol. 2016 Sep;174(5):700-10. doi: 10.1111/bjh.14107. Epub 2016 Apr 26.</citation>
    <PMID>27118319</PMID>
  </reference>
  <reference>
    <citation>Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.</citation>
    <PMID>29859851</PMID>
  </reference>
  <reference>
    <citation>Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013 Oct 10;31(29):3681-7. doi: 10.1200/JCO.2013.48.8783. Epub 2013 Sep 3.</citation>
    <PMID>24002496</PMID>
  </reference>
  <reference>
    <citation>Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.</citation>
    <PMID>29875101</PMID>
  </reference>
  <reference>
    <citation>Chen Y, Pan Y, Guo Y, Zhao W, Ho WT, Wang J, Xu M, Yang FC, Zhao ZJ. Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia. Stem Cell Investig. 2017 Jun 2;4:48. doi: 10.21037/sci.2017.05.04. eCollection 2017. Review.</citation>
    <PMID>28607922</PMID>
  </reference>
  <reference>
    <citation>Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-9. Erratum in: J Clin Oncol. 2004 Feb 1;22(3):576. LoCocco, Francesco [corrected to Lo-Coco, Francesco].</citation>
    <PMID>14673054</PMID>
  </reference>
  <reference>
    <citation>Creutzig U, Kaspers GJ. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2004 Aug 15;22(16):3432-3.</citation>
    <PMID>15310791</PMID>
  </reference>
  <reference>
    <citation>Montesinos P, Lorenzo I, Martín G, Sanz J, Pérez-Sirvent ML, Martínez D, Ortí G, Algarra L, Martínez J, Moscardó F, de la Rubia J, Jarque I, Sanz G, Sanz MA. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008 Jan;93(1):67-74. doi: 10.3324/haematol.11575.</citation>
    <PMID>18166787</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

